In particular, the most common serious adverse events were neutropenia (3.15%, 95% CI: 0.66–13.72%), fatigue (2.50%, 95% CI: 1.22–5.05%), and anemia (2.16%, 95% CI: 0.70–6.45%), followed by adrenal insufficiency (1.70%, 95% CI: 0.50–5.61%) and alanine aminotransferase (ALT) elevation (1.47%, 95% CI: 0.60–3.60%). The gene discussed is GPT; the disease is neutropenia.